Continuous daily sunitinib for recurrent glioblastoma (Q33403947)

26 July 2017

title

Continuous daily sunitinib for recurrent glioblastoma (English)

1 reference

26 July 2017

1 reference

Teri Nguyen Kreisl

1

1 reference

26 July 2017

Perry Smith

2

1 reference

26 July 2017

Joohee Sul

3

1 reference

26 July 2017

Carlos Salgado

4

1 reference

26 July 2017

Fabio M Iwamoto

5

1 reference

26 July 2017

Joanna H Shih

6

1 reference

26 July 2017

Howard A Fine

7

1 reference

26 July 2017

publication date

20 October 2012

1 reference

Journal of Neuro-Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

111

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

41-48

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-012-0988-Z

Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23086433

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23086433

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-012-0988-Z

1 reference

Dimensions Publication ID

26 July 2017

1039682330

0 references

1 reference